Aptevo Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders held on May 15, 2019. Aptevo Therapeutics Inc. is a Delaware corporation with its principal executive offices in Seattle, Washington, and its common stock trades on The Nasdaq Stock Market under the symbol APVO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the annual meeting:
- Proposal No. 1 (Election of Directors): Stockholders elected three nominees to serve until the 2022 Annual Meeting. The voting results were as follows:
| Director Name | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Fuad El-Hibri | 13,852,831 | 6,469,385 | 14,819,353 |
| John E. Niederhuber, M.D. | 13,873,336 | 6,448,880 | 14,819,353 |
| Marvin L. White | 13,861,570 | 6,460,646 | 14,819,353 |
- Proposal No. 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 34,852,250 | 211,021 | 78,298 | N/A |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of votes cast for each director to assess shareholder support levels.
- Confirm the tenure of the newly elected directors (serving until the 2022 Annual Meeting).
- Review the definitive proxy statement on Schedule 14A filed on April 5, 2019, for detailed background on the director nominees and auditor selection.